Answers are grounded in this paper and cite their sources.
Purpose: This study aimed to investigate the efficacy and safety of high-dose multimatrix mesalazine in pediatric patients with active ulcerative colitis (UC). Methods: This was an open-label, uncontrolled, multicenter trial in Japan that included 27 patients aged <17 years with mild-to-moderate active UC. The participants were treated with multimatrix mesalazine at a dose of 80 mg/kg orally once daily for 8 weeks. The primary efficacy endpoint was the achievement of clinical remission, measured based on the ulcerative colitis disease activity index (UC-DAI) score. Results: In the full analysis set, the clinical remission rate based on the UC-DAI score at the end of treatment was 25.9% (two-sided 95% confidence interval [CI]: 11.1%, 46.3%; n=7/27). The lower limit of the two-sided 95% CI exceeded the efficacy threshold (10%), which was predefined based on the placebo group results from clinical studies involving patients with UC. The incidence of adverse events (AEs) was 66.7% (n=18/27) and that of drug-related AEs was 18.5% (n=5/27). No fatalities were reported. Among the study drug-related AEs, only drug intolerance (n=2) was classified as severe, serious, or led to study drug discontinuation. Conclusion: This study demonstrates the clinically meaningful efficacy of high-dose multimatrix mesalazine in the treatment of mild-to-moderate active pediatric UC in Japan. No noteworthy safety concerns beyond the known risks associated with mesalazine were noted.
No takes yet. Share an insight, caveat, or question.
Shimizu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: